Filing Flows › Stoke Therapeutics (STOK) › Q3 2025
Stoke Therapeutics (STOK) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Stoke Therapeutics (STOK) reported revenue of $10.6M for the third quarter 2025 (Q3 2025), +117% from a year earlier and -23% from the quarter before. Operating margin was -405.3%, net loss $38.3M (360.7% of revenue).
Stoke Therapeutics, Q3 2025: revenue $10.6M (+117% year over year), operating margin -405.3%, net loss $38.3M, operating cash flow −$30.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.6M | -23% | +117% |
| Operating profit | −$43.1M | — | — |
| Net earnings | −$38.3M | — | — |
| Operating cash flow | −$30.4M | — | — |
What changed
Revenue was $10.6M in Q3 2025, up 117% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $43.1M, an operating margin of -405.3%. Total costs grew 54% against revenue growth of 117%. The fastest-growing cost line was Research & development (+70%). The quarter ended with a net loss of $38.3M, wider than the previous quarter's $23.5M loss.
Operating cash flow was −$30.4M. Non-cash charges added back $442K of depreciation and $8.0M of share-based compensation. Capital expenditures of $132K exceeded it, leaving free cash flow of −$30.5M.
Questions
What was Stoke Therapeutics' revenue in the third quarter 2025?
Stoke Therapeutics (STOK) reported revenue of $10.6M for the third quarter 2025 (Q3 2025), +117% from a year earlier and -23% from the quarter before.
Was Stoke Therapeutics profitable in the third quarter 2025?
Operating loss was $43.1M (-405.3% of revenue) and net loss $38.3M.
Source: Stoke Therapeutics 10-Q on SEC EDGAR.